Document is current
Any future updates will be listed below
-
Authors
Urs, Meghana
Killekar, Aditya
Builoff, Valerie
Lemley, Mark
Wei, Chih-Chun
Ramirez, Giselle
Kavanagh, Paul
Buckley, Christopher
Slomka, Piotr J. https://orcid.org/0000-0002-6110-938X
-
Funding
Funding for this research was provided by:
Cedars-Sinai Medical Center
- License Information
-
More Information
Article History
Received: 30 June 2025
Accepted: 26 October 2025
First Online: 20 November 2025
Declarations
:
: Institutional Review Board or ethics committee approval was obtained at each study site that participated the phase III Flurpiridaz trial (NCT01347710). The study protocol complied with the Declaration of Helsinki.
: All patients provided written informed consent before undergoing study procedures.
: The authors affirm that human research participants provided informed consent for publication of the images in Fig. .
: Dr. Piotr Slomka and Mr. Paul Kavanagh participate in software royalties for QPS software at Cedars-Sinai Medical Center. Dr. Slomka declares an equity interest in APQ Health and has received research grant support from Siemens Medical Systems and consulting fees from Synektik SA and Novo Nordisk. Dr. Buckley is an employee of GE Healthcare. The remaining authors have no relevant disclosures.
